What the trial was testing
The UltIMMa-1 enrolled 506 patients with plaque psoriasis. The study was sponsored by AbbVie and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
75% achieved 90% clearer skin at 16 weeks — vs. 5% on placebo.
The Lancet · 2018 · NCT02684370
These findings — that of patients with at least 90% skin clearance at week 16 on risankizumab vs. placebo — were published in the The Lancet and represent the headline result of the study.
Researchers tracked outcomes across 506 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with plaque psoriasis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Risankizumab (Skyrizi) is FDA-approved for moderate-to-severe plaque psoriasis and available now. After two starter doses, it is given as a single injection every 12 weeks — among the longest dosing intervals in psoriasis. Ask a dermatologist whether it fits your case.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open plaque psoriasis trials
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.